🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "huge turning point" in the battle against drug-resistant strains of the infection, according to researchers.

A Global Challenge

The sexually transmitted infection are increasing globally, with data suggesting in excess of 82 million new cases each year. Particularly high rates are observed in the African continent and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce therapeutic options currently available.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Gain Authorization

Zoliflodacin, also known as a brand name, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts hope that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This medication, which is also used to treat UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This milestone marks a major breakthrough in the management of superbug gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Testing Results and Global Access

According to findings published in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which combines two antibiotics. The research involved hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the rights to make available and distribute the drug in many regions with limited resources.

Doctors directly involved have voiced hope. Access to a easy-to-administer therapy of this kind is described as a "critical tool" for managing the epidemic. This is viewed as crucial to alleviate the strain of the disease for individuals and to halt the transmission of untreatable gonorrhoea worldwide.